Gene Therapy Protocols pp 203-212
Retroviral Modification of Mesenchymal Stem Cells for Gene Therapy of Hemophilia
Mesenchymal stem cells (MSCs) are a promising target for the delivery of secreted proteins due to their ease of isolation, expansion, and genetic modification. The bleeding disorder hemophilia A results from the deficiency of a secreted blood clotting factor termed factor VIII (fVIII). Hemophilia A could be cured by gene-transfer-based procedures targeting virtually any cell type, including MSCs. Here, we describe methods for retroviral modification of MSCs incorporating a high-expression porcine (HEP)-fVIII transgene and a murine model of hemophilia A. MSCs were isolated from bone marrow of hemophilia A mice, expanded, and transduced ex vivo. Genetically modified MSCs secreted high levels of HEP-fVIII into the conditioned medium. HEP-fVIII was purified from the conditioned medium and demonstrated to have a specific activity, relative electrophoretic mobility, and proteolytic activation pattern similar to HEP-fVIII produced by other commercial cell lines. Collectively, these data support the concept that MSCs can be utilized as a cellular vehicle for successful gene-transfer-based therapy of hemophilia A and other disorders resulting from the deficiency of a secreted protein.
KeywordsMesenchymal stem cells marrow-derived stromal cells gene therapy retroviral vector murine stem cell virus hemophilia A porcine factor VIII
- 9.Peister, A., Mellad, J.A., Larson, B.L., Hall, B.M., Gibson, L.F. and Prockop, D.J. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103, 1662–8 (2004).CrossRefPubMedGoogle Scholar
- 15.Eliopoulos, N., Al-Khaldi, A., Crosato, M., Lachapelle, K. and Galipeau, J. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 10, 478–89 (2003).CrossRefPubMedGoogle Scholar